vs
EPR PROPERTIES（EPR）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是EPR PROPERTIES的1.2倍（$219.9M vs $182.9M），EPR PROPERTIES净利率更高（36.6% vs -1.0%，领先37.6%），EPR PROPERTIES同比增速更快（3.2% vs 2.0%），EPR PROPERTIES自由现金流更多（$269.2M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 4.6%）
EPR地产（前身为娱乐地产信托）是总部位于美国密苏里州堪萨斯城的房地产投资信托企业，专注投资游乐园、电影院、滑雪度假村等娱乐类地产项目，截至2022年共持有353处物业。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
EPR vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.2倍
$182.9M
营收增速更快
EPR
高出1.3%
2.0%
净利率更高
EPR
高出37.6%
-1.0%
自由现金流更多
EPR
多$252.4M
$16.8M
两年增速更快
OFIX
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $182.9M | $219.9M |
| 净利润 | $66.9M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 56.8% | 0.2% |
| 净利率 | 36.6% | -1.0% |
| 营收同比 | 3.2% | 2.0% |
| 净利润同比 | 897.0% | 92.4% |
| 每股收益（稀释后） | $0.80 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EPROFIX
| Q4 25 | $182.9M | $219.9M | ||
| Q3 25 | $182.3M | $205.6M | ||
| Q2 25 | $178.1M | $203.1M | ||
| Q1 25 | $175.0M | $193.6M | ||
| Q4 24 | $177.2M | $215.7M | ||
| Q3 24 | $180.5M | $196.6M | ||
| Q2 24 | $173.1M | $198.6M | ||
| Q1 24 | $167.2M | $188.6M |
净利润EPROFIX
| Q4 25 | $66.9M | $-2.2M | ||
| Q3 25 | $66.6M | $-22.8M | ||
| Q2 25 | $75.6M | $-14.1M | ||
| Q1 25 | $65.8M | $-53.1M | ||
| Q4 24 | $-8.4M | $-29.1M | ||
| Q3 24 | $46.6M | $-27.4M | ||
| Q2 24 | $45.1M | $-33.4M | ||
| Q1 24 | $62.7M | $-36.0M |
毛利率EPROFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率EPROFIX
| Q4 25 | 56.8% | 0.2% | ||
| Q3 25 | 53.5% | -8.3% | ||
| Q2 25 | 62.5% | -7.9% | ||
| Q1 25 | 58.1% | -25.2% | ||
| Q4 24 | 25.5% | -5.3% | ||
| Q3 24 | 51.4% | -9.6% | ||
| Q2 24 | 45.9% | -12.5% | ||
| Q1 24 | 58.8% | -15.6% |
净利率EPROFIX
| Q4 25 | 36.6% | -1.0% | ||
| Q3 25 | 36.5% | -11.1% | ||
| Q2 25 | 42.5% | -6.9% | ||
| Q1 25 | 37.6% | -27.4% | ||
| Q4 24 | -4.7% | -13.5% | ||
| Q3 24 | 25.8% | -13.9% | ||
| Q2 24 | 26.1% | -16.8% | ||
| Q1 24 | 37.5% | -19.1% |
每股收益（稀释后）EPROFIX
| Q4 25 | $0.80 | $-0.05 | ||
| Q3 25 | $0.79 | $-0.57 | ||
| Q2 25 | $0.91 | $-0.36 | ||
| Q1 25 | $0.78 | $-1.35 | ||
| Q4 24 | $-0.19 | $-0.76 | ||
| Q3 24 | $0.53 | $-0.71 | ||
| Q2 24 | $0.51 | $-0.88 | ||
| Q1 24 | $0.75 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.6M | $82.0M |
| 总债务越低越好 | $2.9B | — |
| 股东权益账面价值 | $2.3B | $450.0M |
| 总资产 | $5.7B | $850.6M |
| 负债/权益比越低杠杆越低 | 1.26× | — |
8季度趋势，按日历期对齐
现金及短期投资EPROFIX
| Q4 25 | $90.6M | $82.0M | ||
| Q3 25 | $13.7M | $62.9M | ||
| Q2 25 | $13.0M | $65.6M | ||
| Q1 25 | $20.6M | $58.0M | ||
| Q4 24 | $22.1M | $83.2M | ||
| Q3 24 | $35.3M | $30.1M | ||
| Q2 24 | $33.7M | $26.4M | ||
| Q1 24 | $59.5M | $27.0M |
总债务EPROFIX
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.8B | $157.2M | ||
| Q2 25 | $2.8B | $157.0M | ||
| Q1 25 | $2.8B | $156.9M | ||
| Q4 24 | $2.9B | $157.0M | ||
| Q3 24 | $2.9B | $118.5M | ||
| Q2 24 | $2.8B | $118.0M | ||
| Q1 24 | $2.8B | $118.2M |
股东权益EPROFIX
| Q4 25 | $2.3B | $450.0M | ||
| Q3 25 | $2.3B | $442.5M | ||
| Q2 25 | $2.3B | $458.3M | ||
| Q1 25 | $2.3B | $458.3M | ||
| Q4 24 | $2.3B | $503.1M | ||
| Q3 24 | $2.4B | $525.9M | ||
| Q2 24 | $2.4B | $546.0M | ||
| Q1 24 | $2.4B | $570.3M |
总资产EPROFIX
| Q4 25 | $5.7B | $850.6M | ||
| Q3 25 | $5.5B | $832.6M | ||
| Q2 25 | $5.6B | $837.2M | ||
| Q1 25 | $5.5B | $823.1M | ||
| Q4 24 | $5.6B | $893.3M | ||
| Q3 24 | $5.7B | $867.9M | ||
| Q2 24 | $5.6B | $882.0M | ||
| Q1 24 | $5.7B | $906.0M |
负债/权益比EPROFIX
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.19× | 0.36× | ||
| Q2 25 | 1.20× | 0.34× | ||
| Q1 25 | 1.20× | 0.34× | ||
| Q4 24 | 1.23× | 0.31× | ||
| Q3 24 | 1.19× | 0.23× | ||
| Q2 24 | 1.16× | 0.22× | ||
| Q1 24 | 1.15× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $421.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $269.2M | $16.8M |
| 自由现金流率自由现金流/营收 | 147.1% | 7.6% |
| 资本支出强度资本支出/营收 | 82.9% | 4.9% |
| 现金转化率经营现金流/净利润 | 6.29× | — |
| 过去12个月自由现金流最近4个季度 | $568.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流EPROFIX
| Q4 25 | $421.0M | $27.7M | ||
| Q3 25 | $136.5M | $12.4M | ||
| Q2 25 | $87.3M | $11.6M | ||
| Q1 25 | $99.4M | $-18.4M | ||
| Q4 24 | $393.1M | $23.7M | ||
| Q3 24 | $122.0M | $11.7M | ||
| Q2 24 | $78.7M | $9.0M | ||
| Q1 24 | $99.5M | $-18.6M |
自由现金流EPROFIX
| Q4 25 | $269.2M | $16.8M | ||
| Q3 25 | $132.1M | $2.5M | ||
| Q2 25 | $82.4M | $4.5M | ||
| Q1 25 | $84.7M | $-25.1M | ||
| Q4 24 | $129.2M | $15.2M | ||
| Q3 24 | $121.5M | $6.3M | ||
| Q2 24 | $71.3M | $-360.0K | ||
| Q1 24 | $65.0M | $-29.1M |
自由现金流率EPROFIX
| Q4 25 | 147.1% | 7.6% | ||
| Q3 25 | 72.5% | 1.2% | ||
| Q2 25 | 46.3% | 2.2% | ||
| Q1 25 | 48.4% | -13.0% | ||
| Q4 24 | 72.9% | 7.0% | ||
| Q3 24 | 67.3% | 3.2% | ||
| Q2 24 | 41.2% | -0.2% | ||
| Q1 24 | 38.9% | -15.4% |
资本支出强度EPROFIX
| Q4 25 | 82.9% | 4.9% | ||
| Q3 25 | 2.4% | 4.8% | ||
| Q2 25 | 2.7% | 3.5% | ||
| Q1 25 | 8.4% | 3.5% | ||
| Q4 24 | 148.9% | 4.0% | ||
| Q3 24 | 0.3% | 2.7% | ||
| Q2 24 | 4.2% | 4.7% | ||
| Q1 24 | 20.6% | 5.6% |
现金转化率EPROFIX
| Q4 25 | 6.29× | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.62× | — | ||
| Q2 24 | 1.74× | — | ||
| Q1 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPR
| Experiential Reportable Operating Segment | $173.3M | 95% |
| Education Reportable Operating Segment | $9.5M | 5% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
